Open AccessThe Role of Smoking Status on the Progression‐Free Survival of Non‐Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor ( EGFR ) Mutations Receiving First‐Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta‐Analysis of Prospective Randomized Trials
Author(s) -
Hasegawa Yoshikazu,
Ando Masahiko,
Maemondo Makoto,
Yamamoto Satomi,
Isa Shunichi,
Saka Hideo,
Kubo Akihito,
Kawaguchi Tomoya,
Takada Minoru,
Rosell Rafael,
Kurata Takayasu,
Ou SaiHong Ignatius
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0285
Subject(s) - epidermal growth factor receptor , medicine , lung cancer , cancer research , tyrosine kinase , epidermal growth factor , oncology , receptor
Background. Univariate analyses from several randomized phase III trials seemed to suggest ever‐smokers with advanced mutated epidermal growth factor receptor ( EGFRm ) non‐small cell lung cancer (NSCLC) did not seem to benefit from EGFR tyrosine kinase inhibitors (TKIs) as first‐line treatment when compared with platinum‐doublet chemotherapy as measured by progression‐free survival (PFS). Methods. A literature‐based meta‐analysis of PFS outcomes as measured by log‐transformed pooled hazard ratio (HR) was performed using a random‐effect model. Pooled HRs for smoking status, age, gender, ethnicity, type of EGFR mutation, and EGFR TKI were obtained. Comparison of the pooled HR was performed by metaregression analysis. Results. Among the 1,649 EGFRm NSCLC patients analyzed from 7 prospective randomized trials (WJTOG3405, NEJ002, EURTAC, OPTIMAL, LUX Lung‐3, LUX Lung‐6, and ENSURE), 83.7% were Asians, and 30.0% were ever‐smokers. An equal percentage of ever‐smokers received doublet chemotherapy (30.2%) or EGFR TKI (30.0%). The pooled HR for PFS was 0.29 (95% confidence interval [CI]: 0.21–0.39) for never‐smokers and 0.54 (95% CI: 0.38–0.76) for ever‐smokers ( p < .007 by metaregression). The pooled PFS HR for exon 19 deletion was 0.25 (95% CI: 0.19–0.31) and 0.44 for exon 21 substitution (95% CI: 0.34–0.57) ( p < .001 by metaregression analysis). The pooled PFS HR was 0.33 (95% CI: 0.24–0.46) for Asians and 0.48 for non‐Asians (95% CI: 0.28–0.84) ( p = .261 by metaregression analysis). Conclusion. EGFRm NSCLC patients derived significant PFS benefit from TKI over platinum‐doublet chemotherapy as first‐line treatment regardless of smoking status; however, PFS benefit is significantly better in never‐smokers by metaregression analysis.